{"id":751579,"date":"2023-04-26T16:25:49","date_gmt":"2023-04-26T20:25:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2023-04-26T16:25:49","modified_gmt":"2023-04-26T20:25:49","slug":"neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">GAITHERSBURG, Md., April  26, 2023  (GLOBE NEWSWIRE) &#8212; NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1\/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 \u2013 June 6, 2023.<\/p>\n<p>\n        <strong>Poster Presentation:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Title: <\/strong>An Analysis of a First-In-Human Study of NEXI-001 Donor-Derived Antigen-Specific CD8+ T-Cell Treatment of Relapsed AML after Allogeneic Hematopoietic Cell Transplantation (HCT)<\/p>\n<p>\n        <strong>Abstract #:<\/strong> 7043 (Poster Board #173)<\/p>\n<p>\n        <strong>Session Title:<\/strong> Hematologic Malignancies \u2013 Leukemia, Myelodysplastic Syndromes, and Allotransplant<\/p>\n<p align=\"justify\">\n        <strong>Authors:<\/strong> Monzr M. Al Malki, MD<sup>1<\/sup>, Juan C. Varela MD, PhD<sup>2<\/sup>, Sumithira Vasu, MBBS<sup>3<\/sup>, Dipenkumar Modi, MD<sup>4<\/sup>, Suzanne Afonso-Smith, PhD<sup>5<\/sup>, Sojung Kim, PhD<sup>5<\/sup>, Emily Lu, PhD<sup>5<\/sup>, Robert D. Knight, MD<sup>5<\/sup>, and Mathias Oelke, PhD<sup>5<\/sup><\/p>\n<p align=\"justify\">(1)Hematology\/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, (2)Advent Health Blood and Marrow Transplant Program, Orlando, FL, (3)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus Ohio, (4)Division of Oncology, Karmanos Cancer Center\/Wayne State University, Detroit, MI, (5)NexImmune, Inc., Gaithersburg, MD<\/p>\n<p>\n        <strong>About\u00a0NexImmune<\/strong>\n      <\/p>\n<p align=\"justify\">NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body\u2019s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune\u2019s approach is a proprietary Artificial Immune Modulation (AIM\u2122) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities. NexImmune is focused on developing injectable AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology, autoimmune disorders and infectious diseases.<\/p>\n<p>For more information, visit\u00a0<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TnKLiyiz0-aPBmrE5-4GYBUyZvVKH8vAugTGw7gW7n8JhhcNSrUelF2veTmrsB_ZvWCIZ_el5bkt8NpJb84_9g==\" rel=\"nofollow noopener\" target=\"_blank\">www.neximmune.com<\/a><\/u>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may contain \u201cforward-looking\u201d statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the \u201cCompany\u201d). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the full year ended December 31, 2021; the sufficiency of the Company\u2019s current cash, cash equivalents and marketable securities to fund its planned operations into the fourth quarter of 2023; our planned and ongoing clinical trials for the Company\u2019s product candidates, including NEXI-001, NEXI-002 and NEXI-003; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical trials and preclinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the \u201cRisk Factors\u201d section of our Annual Report on Form 10-K for the year ended December\u00a031, 2022 filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March\u00a028, 2023, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company\u2019s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Investors and Media:<\/strong><br \/>\n        <br \/>Chad Rubin, SVP Corporate Affairs and Investor Relations<br \/>NexImmune, Inc.<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LFoy-xjitDpJvWuI-5_ub6SjwcKBesDZCoH79WCIfgVFuBG4w5d9bAJmQkqkA7Bmjtt7juVpG5RSU7nwhp-BgX7rPnHUdLwmacfksHYhYDg=\" rel=\"nofollow noopener\" target=\"_blank\">crubin@neximmune.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTMzOWFkZTItNjIzYi00OTFhLWJkODYtOWIxMGMyNzljMGNiLTEwOTU3NzA=\/tiny\/NexImmune-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) &#8212; NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1\/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 \u2013 June 6, 2023. Poster Presentation: Title: An Analysis of a First-In-Human Study of NEXI-001 Donor-Derived Antigen-Specific CD8+ T-Cell Treatment of Relapsed AML after Allogeneic Hematopoietic Cell Transplantation (HCT) Abstract #: 7043 (Poster Board #173) Session Title: Hematologic Malignancies \u2013 Leukemia, Myelodysplastic Syndromes, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751579","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) &#8212; NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1\/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 \u2013 June 6, 2023. Poster Presentation: Title: An Analysis of a First-In-Human Study of NEXI-001 Donor-Derived Antigen-Specific CD8+ T-Cell Treatment of Relapsed AML after Allogeneic Hematopoietic Cell Transplantation (HCT) Abstract #: 7043 (Poster Board #173) Session Title: Hematologic Malignancies \u2013 Leukemia, Myelodysplastic Syndromes, &hellip; Continue reading &quot;NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T20:25:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NexImmune Announces Presentation of Phase 1\\\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting\",\"datePublished\":\"2023-04-26T20:25:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"wordCount\":714,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\",\"name\":\"NexImmune Announces Presentation of Phase 1\\\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=\",\"datePublished\":\"2023-04-26T20:25:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NexImmune Announces Presentation of Phase 1\\\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","og_description":"GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) &#8212; NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1\/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 \u2013 June 6, 2023. Poster Presentation: Title: An Analysis of a First-In-Human Study of NEXI-001 Donor-Derived Antigen-Specific CD8+ T-Cell Treatment of Relapsed AML after Allogeneic Hematopoietic Cell Transplantation (HCT) Abstract #: 7043 (Poster Board #173) Session Title: Hematologic Malignancies \u2013 Leukemia, Myelodysplastic Syndromes, &hellip; Continue reading \"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T20:25:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting","datePublished":"2023-04-26T20:25:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"},"wordCount":714,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","name":"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=","datePublished":"2023-04-26T20:25:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ3OSM1NTU5MzU1IzIwODQxOTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neximmune-announces-presentation-of-phase-1-2-clinical-data-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NexImmune Announces Presentation of Phase 1\/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751579"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751579\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}